Interesting news from ESMO conference about Novartis's lutetium-PSMA drug, Pluvicto.
https://www.fiercepharma.com/pharma/novartis-booming-pluvicto-posts-hot-and-cold-results-earlier-prostate-cancer
This is the same drug whose effect reportedly was boosted by Veyonda in the company's LUPIN study. Maybe Novartis and NOX need to talk.
LUPIN again
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.04M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14100 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 13221 | 4 |
View Market Depth
| Last trade - 16.12pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
0.000 ( 11.5 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 6.9¢ | 6.9¢ | 2941 | ||
| Last updated 11.56am 20/05/2024 ? | |||||
| NOX (ASX) Chart |
Day chart unavailable